Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Bayer completes sale of H.C. Starck to Advent International and The Carlyle Group

Leverkusen / February 1, 2007 – The Bayer Group has sold its subsidiary H.C. Starck to Advent International and The Carlyle Group. As of the closing on February 1, 2007, the two financial investors have acquired the Goslar-based manufacturer of metal and ceramic powders, specialty chemicals, and parts made from advanced ceramics and refractory metals. The antitrust authorities in the United States and the European Union have already cleared the transaction, which was agreed on November 23, 2006.

The transaction value of approximately EUR 1.2 billion comprises a cash component of more than EUR 700 million and the assumption of financial liabilities and personnel-related commitments totaling some EUR 450 million. As planned, the proceeds will help to finance Bayer's acquisition of Schering. The divestment reduces Bayer's net debt by about EUR 1 billion.

About Advent International:
Advent International is one of the world's leading private equity firms, with over EUR 8 billion (US$ 10 billion) in cumulative capital raised and offices in 14 countries across Western and Central Europe, North America, Latin America and Asia. Since its inception in 1984, Advent has invested in more than 500 companies in 35 countries and has taken over 130 of these businesses public on major stock exchanges worldwide. Advent has a proven track record of success in the German market, having concluded nine transactions in the past two years. In 2004, for example, Advent and Carlyle jointly acquired HT Troplast, the world's leading manufacturer of vinyl profiles for windows and doors.

About The Carlyle Group:
The Carlyle Group is a global private equity firm with more than US$ 46 billion (EUR 36 billion) under management. Carlyle invests in buyouts, venture and growth capital, real estate and leveraged finance in North America, Europe and Asia. Focus industries are aerospace, automotive & transportation, consumer & retail, chemicals, energy & power, healthcare, industrial, technology & business services, and telecom & media. Since 1987, Carlyle has invested total equity capital of US$24 billion (EUR 19 billion) in 576 transactions.

Leverkusen, February 1, 2007

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Ilia Kürten (+49-214-30-35426)
Ute Menke (+49-214-30-33021)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)

Forward-Looking Statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.